Molecular Formula | C32H55BrN4O |
Molar Mass | 591.71 |
Melting Point | 91-92° |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | Inert atmosphere,Room Temperature |
In vitro study | Thonzonium bromide inhibits RANKL-induced OC formation, the appearance of OC-specific marker genes and bone-resorbing activity in vitro. Thonzonium bromide blocks the RANKL-induced activation of NF-κB, ERK and c-Fos as well as the induction of NFATc1 which is essential for OC formation. Thonzonium bromide disrupts F-actin ring formation resulting in disturbances in cytoskeletal structure in mature OCs during bone resorption. Thonzonium bromide exhibits protective effects in an in vivo murine model of LPS-induced calvarial osteolysis. |
Hazard Symbols | Xn - Harmful![]() |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. R41 - Risk of serious damage to eyes R37/38 - Irritating to respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
HS Code | 2933599550 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.69 ml | 8.45 ml | 16.9 ml |
5 mM | 0.338 ml | 1.69 ml | 3.38 ml |
10 mM | 0.169 ml | 0.845 ml | 1.69 ml |
5 mM | 0.034 ml | 0.169 ml | 0.338 ml |
biological activity | Thonzonium bromide, an antibacterial agent structurally similar to Farnesol (HY-Y0248A), A monocationic surfactant that inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibited proton transport in a dose-dependent manner (EC50=69 μm). |